Pain Therapeutics Inc (PTIE.OQ)

PTIE.OQ on NASDAQ Stock Exchange Global Select Market

2.37USD
1 Aug 2013
Price Change (% chg)

$-0.05 (-2.07%)
Prev Close
$2.42
Open
$2.46
Day's High
$2.46
Day's Low
$2.32
Volume
37,474
Avg. Vol
125,817
52-wk High
$5.86
52-wk Low
$2.18

PTIE.OQ

Chart for PTIE.OQ

About

Pain Therapeutics, Inc. is a biopharmaceutical company that develops drugs. The Company has four drug candidates in clinical programs, including REMOXY, abuse-resistant hydromorphone, abuse-resistant hydrocodone and a radio-labeled monoclonal antibody to treat metastatic melanoma. It is also working on a new treatment for... (more)

Overall

Beta: 0.49
Market Cap (Mil.): $109.70
Shares Outstanding (Mil.): 45.33
Dividend: 0.75
Yield (%): --

Financials

  PTIE.OQ Industry Sector
P/E (TTM): -- 47.13 37.76
EPS (TTM): -0.10 -- --
ROI: -6.02 -2.58 18.76
ROE: -13.23 -2.66 19.59
Search Stocks

RBS names former regulator Pain as head of conduct

LONDON, May 27 - State-backed British lender Royal Bank of Scotland has appointed Jon Pain, a former director at the country's financial services regulator, as its new head of conduct, it said on Monday.

27 May 2013

Pfizer yet to decide on Pain Therapeutics' painkiller

- Pfizer Inc said it could not decide whether to pursue regulatory approval for Pain Therapeutics Inc's painkiller Remoxy, for which the United States Food and Drug Administration sought additional studies.

10 May 2013

Pain Therapeutics, Durect shares soar on Pfizer's Remoxy comments

- Shares of Pain Therapeutics Inc and Durect Corp rose more than 40 percent after partner Pfizer Inc said it is in talks with U.S. health regulators to find a way forward on the companies' painkiller, Remoxy.

30 Apr 2013

INDIA PRESS-PE Quadria buys Milestone Religare Investment - PTI in Economic Times

Govt plans fund to help boost sagging exports - Economic Times

21 Mar 2013

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Zacks Investment Research Inc.
$12.00
Provider: TheStreet.com Ratings
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks